5α-reductases and their inhibitors

International Journal of Immunopathology and Pharmacology

Volumn 9, Issue 1, 1996, Pages 33-38

  Spera, Giovanni ^a   Lubrano, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

G CSF, GM CSF and IL3; peripheral CFU; urinary polypeptide

Indexed keywords

3 PHOSPHONIC ACID DERIVATIVE; 4 AZASTEROID DERIVATIVE; 6 AZASTEROID DERIVATIVE; 8 CHLORO 1,2,3,4,4A,5,6,10B OCTAHYDRO 4 METHYLBENZO[F]QUINOLIN 3(2H) ONE; ANDROSTENEDIONE; AZELAIC ACID; BENZOQUINOLONE DERIVATIVE; BENZOYLAMINOPHENOXYBUTANOIC ACID DERIVATIVE; DEOXYCORTICOSTERONE; DEOXYCORTICOSTERONE ACETATE; DIAZOKETONE STEROID DERIVATIVE; FINASTERIDE; ISOENZYME; PHENAZINE DERIVATIVE; PROGESTERONE; SECOSTEROID DERIVATIVE; STEROID; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ZINC SULFATE;

ACNE; ALOPECIA; ANDROGEN METABOLISM; CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HIRSUTISM; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW;

EID: 0029952276     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463209600900107     Document Type: Review

References (37)

1. Levine, AC. 1995. Pathogenesis and medical management of benign prostatic hyperplasia. Trends Endocrinol. Metab. 6:128
2. Imperato-McGinley J., L. Guerrero, T. Gautier and R.E. Peterson. 1974. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186:1213
3. Imperato-McGinley J., T. Gautier, K. Zirinski et al. 1992. Prostate visualisation studies in males homozygous and heterozygous for 5α-reductase deficiency. N. Engl. J. Med. 327: 1185
4. Ebling F.J.G. 1986. Hair follicles and associated glands as androgen targets. Clin. Endocrinol. Metab. 15:319
5. Serafini P., F. Ablan and R.A. Lobo. 1985. 5α-reductase activity in the genital skin of hirsute women. J. Clin. Endocrinol. Metab. 60: 532
6. Li X., C. Chen, S.M. Singh and F. Labrie. 1995. The enzyme and inhibitors of 4-ene-3oxosteroid 5α-oxidoreductase. Steroids 60:430
7. Jenkins E.P., S. Andersson, J. Imperato Mc-Ginley, J.D. Wilson and D.W. Russel. 1992 Genetic and pharmacological evidence for more than one human steroid 5α reductase. J. Clin. Invest. 89: 293
8. Thigpen A.E., D.L. Davis, A. Milatovich, B.B. Mendonca, J. Imperato -McGinley, J.E. Griffin, U. Francke, J.D. Wilson and D.W. Russel. 1992. Molecular genetics of steroid 5α reductase 2 deficiency. J. Clin. Invest. 90: 799
9. Thigpen A.E., R.I. Silver, J.M. Guileyardo, M.L. Casey, J.D. McConnel and D.W. Russel. 1993. Tissue distribution and ontogeny of steroid 5α reductase isozyme expression. J. Clin. Invest. 92: 903
10. Silver R.J., E.I. Wiley, J.M. Guileyardo, J.D. McConnel and D.W. Russel. 1994. Cell type specific expression of steroid 5α reductase 2. J. Urol. 152:438
11. Berman D.M. and D.W. Russell. 1993. Cell-type expression of rat steroid 5α reductase isozymes. Proc. Natl. Acad. Sci. USA 90: 9359
12. Griffin J.E. and J.D. Wilson. 1989. The androgen resistance syndromes: 5α reductase deficiency, testicular feminization, and related disorders. In The metabolic basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D, ed. McGraw-Hill New York, p. 1919
13. Ebling F.J.G. 1986: Hair follicles and associated glands as androgen targets. Clin. Endocrinol. Metab. 15, 319
14. Schmidt J.A. and H.U. Schweikert. 1986. Testosterone and epitestosterone metabolism of single hairs in 5 patients with 5α-reductase deficiency. Acta Endocrinol. 113:588
15. Harris G.B., B. Azzolina, W. Baginski, G. Cimis, G.H. Rasmusson, R.L. Tolman, C.R.H. Raetz and K. Ellsworth. 1992. Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc. Natl. Acad. Sci. USA 89: 10787
16. Rosenfield R.L. 1989. The ovary and female sexual maturation. In Clinical pediatric endocrinology, 2nd. ed. Kaplan Sa, ed., WB Saunders Philadelphia: p. 259
17. Imperato -McGinley J., T. Gautier, L.Q. Cai, B. Yee, J. Epstein and P. Pochi. 1993. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J. Clin. Endocrinol. Metab. 76: 524
18. Jones C.D., J.E. Audia, D.E. Lawhorn, L.A. McQuaid, B.L. Neubauer, A.J. Pike, P.A. Pennington, N.B. Stamm, R.E. Toomey and K.S. Hirsch. 1993. Nonsteroidal inhibitors of human type 1 steroid 5α-reductase. J. Med. Chem. 36:421
19. Rasmusson G.H., G.F. Reynolds, N.G. Steinberg, E. Walton, G.F. Patel, T. Liang, M.A. Cascieri, A.H. Cheung, J.R. Brooks and C. Berman. 1986. Azasteroids: structure activity relationships for inhibition of 5α-reductase and of androgen receptor binding. J. Med. Chem. 29: 2298
20. Mellin T.N., R.D. Busch and G.H. Rasmusson. 1993. Azasteroids as inhibitors of testosterone 5α-reductase in mammalian skin. J. Steroid Biochem. Mol. Biol. 44:121
21. Mc Connel J.D., J.D. Wilson, F.W. George, J. Geller, F. Pappas and E. Stoner. 1992. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with Benign Prostatic Hyperplasia. J. Clin. Endocrinol. Metab. 74: 505
22. Vermeulen A., V.A. Giagulli, P. De Schepper, A. Buntinx and E. Stoner. 1989. Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in human. Prostate 14:45
23. De Schepper P.J., J. Imperato-McGinley, A.V. Hecken, I. De Lepeleire, A. Buntinx, J. Carlin, M.H. Gressi and E. Stoner. 1991. Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5α-reductase inhibitor. Steroids 56: 469
24. Ciotta L., A. Cianci, A.E. Calogero, M.A. Palumbo, E. Marletta, A. Sciuto and G. Palumbo. 1995. Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril. 64: 299
25. Fruzzetti F., D. De Lorenzo, D. Parrini and C. Ricci. 1994. Effects of finasteride, a 5α-reductase inhibitor, on circulating androgen and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab. 79: 831
26. Diani A.R., J. Mulholland, K.L. Shull, M.F. Kubicek, G.A. Johnson, H.J. Schostarez, M.N. Brunden and A.E. Buhl. 1992. Hair growth effects of oral administration of finasteride, a steroid 5α-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J. Clin. Endocrinol. Metab. 74: 345
27. Rittmaster R.S., H. Uno, M.L. Povar, T.N. Mellin and D.L. Loriaux. 1987. The effects of N,N-diethyl-4-methyl-3oxo-4aza-5α-androstane-17(-carboxamide, a 5α-reductase inhibitor and antiandrogen, on the development of baldness in the stumptail macaque. J. Clin. Endocrinol. Metab. 65: 188
28. Oesterling J. 1994. Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology 43 (suppl 2):7
29. Mocellini A.I., R. Gardiner, V. Marshall, W. Johnson, G. Bartsch, C.P. Schmidbauer, H. Mossing, P.J. Van Cangh, L.J. Denis, S. Arap et al. 1993. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22:291
30. Gormley G.J., E. Stoner, R.C. Bruskewitz, J. Imperato-Mc Ginley, P.C. Walsh, J.D. McConnel, G.L. Andriole, J. Geller, B.R. Bracken and J.S. Tenover. 1992. The finasteride study group: The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med 327: 1184
31. Stoner E. 1994. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch. Int. Med. 154:83
32. Stoner E. 1994. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43:284
33. Geller J. 1995. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur. Urol. 27:267
34. Moore E., B. Bracken, W. Bremmer, J. Geller, J. Imperato-McGinley, J. McConnel, J. Roy, L. Tenover, F. Pappas, T. Cook, G. Gormley and E. Stoner. 1995. Proscar: five-year experience. Eur. Urol. (in press)
35. Lepor H. and E. Stoner. 1995. Long-term results of medical therapies for benign prostatic hyperplasia. Curr. Opinion. Urol. 5:18
36. Tammela T.L.J. and M.J. Kontturi. 1995. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J. Urol. 154 (in press)
37. Geller J., A. Kirschenbaum, H. Lepor and A.C. Levine. 1995. Therapeutic controversies: clinical treatment of benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 80:745